SEC Form 4 · accession 0001104659-18-000368
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Berndt Modig
Director
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 8:39 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 29, 2017 | M | 77,914 | $0.90 | A | 77,914 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.90 | Dec 29, 2017 | M | 77,914 | D | — | Mar 17, 2025 | Common Stock | 77,914 | 7,086 | D |
Explanation of responses
- F1This option vests over a period of three years, with one third of the common shares underlying the option having vested on March 18, 2016 and the remainder vesting in eight equal quarterly installments thereafter.
Remarks
Exhibit 24 - Power of Attorney